ACADIA PHARMACEUTICALS INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2025 was $44.37M, a 2722.52% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2024 was $1.57M, a 92.26% decline from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2023 was $20.31M, a 448.15% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2022 was $3.71M, a 71.17% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $44.37M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $1.57M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $20.31M 10-K · filed 2026-02-26 | |
| 2022-12-31 | $3.71M 10-K · filed 2025-02-27 | |
| 2021-12-31 | $12.85M 10-K · filed 2024-02-28 | |
| 2020-12-31 | $73.83M 10-K · filed 2022-03-01 | |
| 2018-12-31 | $4.43M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $26.66M 10-K · filed 2020-02-27 | |
| 2016-12-31 | $18.00M 10-K · filed 2019-02-27 | |
| 2015-12-31 | $12.99M 10-K · filed 2018-02-27 | |
| 2014-12-31 | $6.41M 10-K · filed 2017-02-28 | |
| 2013-12-31 | $3.44M 10-K · filed 2016-02-29 | |
| 2012-12-31 | $453.00K 10-K · filed 2015-02-26 | |
| 2011-12-31 | $13.00K 10-K · filed 2014-02-27 | |
| 2010-12-31 | $11.00K 10-K · filed 2013-03-12 | |
| 2009-12-31 | $74.00K 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |